Publications by authors named "Alfred Sandrock"

Claim this Profile
R
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Tianle Chen, John O'Gorman, Carmen Castrillo-Viguera, Rajasimhan Rajagovindan, Gioacchino G Curiale, Alfred Sandrock

Alzheimers Dement· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Ih Chang, Ludwig Kappos, Gavin Giovannoni, Peter A Calabresi, Alfred Sandrock

Mult Scler· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Edward D Plowey, Thierry Bussiere, Raj Rajagovindan, Jennifer Sebalusky, Stefan Hamann, Alfred Sandrock

Acta Neuropathol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.
Alfred Sandrock

Ann Neurol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring treatment response to advance precision medicine for multiple sclerosis.
Peter A Calabresi, Ludwig Kappos, Gavin Giovannoni, Tatiana Plavina, Irene Koulinska, Alfred Sandrock

Ann Clin Transl Neurol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari, Alfred W Sandrock

CNS Drugs· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
Tatiana Plavina, Carol M Singh, Dipen Sangurdekar, Carl de Moor, Bob Engle, Alfred W Sandrock

JAMA Netw Open· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, Peter M Andersen, Nazem Atassi, Alfred Sandrock

N Engl J Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Alfred W Sandrock, Wildon Farwell

Adv Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
Darryl C De Vivo, Enrico Bertini, Kathryn J Swoboda, Wuh-Liang Hwu, Thomas O Crawford, Alfred W Sandrock

Neuromuscul Disord· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Alfred Sandrock

Nature· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Alfred Sandrock

Nature· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Gary Bloomgren, Sandra Richman, Christophe Hotermans, Meena Subramanyam, Susan Goelz, Alfred Sandrock

N Engl J Med· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
Carmen Bozic, Sandra Richman, Tatiana Plavina, Amy Natarajan, James V Scanlon, Alfred Sandrock

Ann Neurol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-JC virus antibodies: implications for PML risk stratification.
Leonid Gorelik, Michaela Lerner, Sarah Bixler, Mary Crossman, Brian Schlain, Alfred Sandrock

Ann Neurol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Richard A Rudick, Paul W O'Connor, Chris H Polman, Andrew D Goodman, Soma S Ray, Alfred W Sandrock

Ann Neurol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Ernst-Wilhelm Radue, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Alfred W Sandrock

J Neurol Sci· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: To PMID 19798640.
Carmen Bozic, Julia LaGuette, Alfred Sandrock

Ann Neurol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Leonid Gorelik, Susan Goelz, Alfred W Sandrock

N Engl J Med· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab and central nervous system lymphoma: no clear association.
Carmen Bozic, Julia LaGuette, Michael A Panzara, Alfred W Sandrock

Ann Neurol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LINGO-1 and its role in CNS repair.
Sha Mi, Alfred Sandrock, Robert H Miller

Int J Biochem Cell Biol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.
Richard A Rudick, Sha Mi, Alfred W Sandrock

Expert Opin Biol Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Ludwig Kappos, Ralf Gold, David H Miller, David G Macmanus, Eva Havrdova, Alfred W Sandrock

Lancet· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More on melanoma with transdifferentiation.
Michael A Panzara, Carmen Bozic, Alfred W Sandrock

N Engl J Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Richard A Rudick, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Alfred W Sandrock

N Engl J Med· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis